Article
Cell Biology
Thomas M. O'Connell, Lilian Golzarri-Arroyo, Fabrizio Pin, Rafael Barreto, Stephanie L. Dickinson, Marion E. Couch, Andrea Bonetto
Summary: The search for early biomarkers of cancer cachexia is crucial, with amino acids and lipoproteins identified as the earliest significant changes. Metabolic alterations appear before weight loss, providing a new avenue for early detection in clinical settings.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Christiano R. R. Alves, Eric J. Eichelberger, Willian das Neves, Marcio A. C. Ribeiro, Luiz R. G. Bechara, Vanessa A. Voltarelli, Ney R. de Almeida, Lars Hagen, Animesh Sharma, Julio C. B. Ferreira, Kathryn J. Swoboda, Geir Slupphaug, Patricia C. Brum
Summary: The study found that tumor-bearing rats exhibited severe muscle atrophy exclusively in glycolytic fibers, with no significant changes in oxidative muscles.
Article
Oncology
Riccardo Ballaro, Patrizia Lopalco, Valentina Audrito, Marc Beltra, Fabrizio Pin, Roberto Angelini, Paola Costelli, Angela Corcelli, Andrea Bonetto, Hazel H. Szeto, Thomas M. O'Connell, Fabio Penna
Summary: Cancer cachexia is a debilitating syndrome caused by tumor growth and chemotherapy, affecting skeletal muscle metabolism and function. The study focused on using the mitochondria-targeted compound SS-31 to counteract cachexia by improving metabolic function, showing effectiveness in early disease stages but limited effects in late refractory cachexia. Targeting mitochondrial function may be important in preventing cancer cachexia, with potential for multi-modal therapies including SS-31.
Article
Physiology
Willian das Neves, Christiano R. R. Alves, Ana Paula de Souza Borges, Gilberto de Castro Jr
Summary: This study found a potential association between low serum creatinine levels and skeletal muscle atrophy in NSCLC patients, especially among male patients. Serum creatinine levels may serve as a potential prognostic biomarker for muscle atrophy in NSCLC patients.
FRONTIERS IN PHYSIOLOGY
(2021)
Review
Oncology
Claudia Bordignon, Bethania S. dos Santos, Daniela D. Rosa
Summary: Cachexia is a common syndrome in cancer patients, especially those with advanced tumors, characterized by weight loss, muscle wasting, and cardiac dysfunction. This review examines the manifestations of cachexia and the potential role of physical exercise in preventing or reversing this syndrome in cancer patients.
Article
Gastroenterology & Hepatology
Zhijun Zhou, Yu Ren, Jingxuan Yang, Mingyang Liu, Xiuhui Shi, Wenyi Luo, Kar-Ming Fung, Chao Xu, Michael S. Bronze, Yuqing Zhang, Courtney W. Houchen, Min Li
Summary: In this study, we found that ACSS2 enhances nonselective macropinocytosis and muscle wasting in pancreatic cancer through metabolic reprogramming, revealing the potential mechanism behind these processes.
Article
Cell Biology
Lulu Wei, Ranran Wang, Junaid Wazir, Kai Lin, Shiyu Song, Li Li, Wenyuan Pu, Chen Zhao, Yong Wang, Zhonglan Su, Hongwei Wang
Summary: This study aimed to explore the efficiency of 2-DG in blocking Cori cycle activity and its therapeutic effect on cachexia-associated muscle wasting. The results showed that 2-DG significantly ameliorated cancer cachexia-associated muscle wasting and increased mitochondrial bioenergetic capacity.
Review
Oncology
Louisa Tichy, Traci L. Parry
Summary: Cancer-induced cardiac cachexia is a major cause of death in cancer patients, characterized by severe cardiac muscle wasting and dysfunction. The exact molecular mechanisms are not fully understood, but researchers have identified different stages of progression and potential biomarkers for detection and monitoring. Current treatment options are limited and there is a need for further research to develop effective interventions.
Review
Oncology
Mit Joshi, Bhoomika M. Patel
Summary: Cancer cachexia is a wasting syndrome driven by chronic inflammation and high energy expenditure. Uncoupling proteins (UCPs) play an important role in cancer cachexia by increasing the body's overall energy utilization. This review provides new insights into the role of UCPs in cancer cachexia and highlights their potential as a target for treating this syndrome.
Article
Oncology
Andrea David Re Cecconi, Mara Barone, Mara Forti, Martina Lunardi, Alfredo Cagnotto, Mario Salmona, Davide Olivari, Lorena Zentilin, Andrea Resovi, Perla Persichitti, Dorina Belotti, Federica Palo, Nobuyuki Takakura, Hiroyasu Kidoya, Rosanna Piccirillo
Summary: The study aimed to assess the role of apelin in combating muscle loss during cancer cachexia. The results showed that although apelin exhibited beneficial effects against muscle atrophy in in vitro models, it failed to do so in in vivo models due to undesired apelin resistance. This study uncovering apelin resistance highlights potential issues in apelin-based therapy for cancer cachexia.
Article
Biochemistry & Molecular Biology
Lauren E. Rentz, Marcella A. Whetsell, Stuart A. Clayton, Alan D. Mizener, Ida Holaskova, Matthew G. Chapa, Emily H. Hoblitzell, Timothy D. Eubank, Emidio E. Pistilli
Summary: Breast cancer incidence is rare in men, but the lack of screening results in lower survival rates compared to women. The study found that there are sexually dimorphic responses in skeletal muscle function and molecular composition to breast tumors. The findings provide insights into therapeutic strategies targeting tumor-associated muscle alterations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Wenlan Li, Jennifer Trieu, Ronnie Blazev, Benjamin L. Parker, Kate T. Murphy, Kristy Swiderski, Gordon S. Lynch
Summary: Cancer cachexia is a common condition in cancer patients, where loss of skeletal muscle mass affects treatment response and quality of life. Sulforaphane (SFN), a natural antioxidant found in cruciferous vegetables, has been shown to decrease oxidative stress. This study investigated whether SFN could attenuate muscle wasting induced by cancer cells and chemotherapy, and found that SFN was able to prevent muscle atrophy and activate antioxidant signaling pathways.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
(2023)
Review
Cell Biology
Marc Beltra, Fabrizio Pin, Riccardo Ballaro, Paola Costelli, Fabio Penna
Summary: Cancer cachexia is a frequently neglected syndrome with complex pathogenesis impacting patients' quality of life, and no effective therapeutic approach has been identified yet.
Article
Multidisciplinary Sciences
Aneesha Dasgupta, Daniel F. Gibbard, Rebecca E. Schmitt, Paige C. Arneson-Wissink, Alexandra M. Ducharme, Elizabeth S. Bruinsma, John R. Hawse, Aminah Jatoi, Jason D. Doles
Summary: Cancer cachexia is a major hurdle in cancer management, lacking effective therapies. KLF10 upregulation is found in multiple wasting contexts and targeting KLF10 can mitigate cancer-associated muscle wasting. TGF-beta, a known inducer of KLF10, plays a critical role in the etiology of pancreatic cancer-associated muscle wasting.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Review
Oncology
Tania Setiawan, Ita Novita Sari, Yoseph Toni Wijaya, Nadya Marcelina Julianto, Jabir Aliyu Muhammad, Hyeok Lee, Ji Heon Chae, Hyog Young Kwon
Summary: Muscle wasting is the progressive loss of skeletal muscle mass and strength, which can be caused by physiological changes or various diseases. Cancer cachexia is a syndrome characterized by the loss of skeletal muscle mass, leading to functional impairment and reduced quality of life. It is caused by inflammation and an increase in muscle breakdown. This article summarizes the molecular networks that regulate muscle mass, discusses the multi-organ roles in cancer cachexia, and explores potential therapeutic approaches, as there are currently no approved drugs for this condition.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Fabrizio Pin, Leah J. Novinger, Joshua R. Huot, Robert A. Harris, Marion E. Couch, Thomas M. O'Connell, Andrea Bonetto
Article
Endocrinology & Metabolism
Hannah M. Davis, Alyson L. Essex, Sinai Valdez, Padmini J. Deosthale, Mohammad W. Aref, Matthew R. Allen, Andrea Bonetto, Lilian I. Plotkin
Article
Cell Biology
Joshua R. Huot, Leah J. Novinger, Fabrizio Pin, Andrea Bonetto
DISEASE MODELS & MECHANISMS
(2020)
Article
Medicine, Research & Experimental
Joshua R. Huot, Leah J. Novinger, Fabrizio Pin, Ashok Narasimhan, Teresa A. Zimmers, Thomas M. O'Connell, Andrea Bonetto
Article
Geriatrics & Gerontology
Joshua R. Huot, Fabrizio Pin, Ashok Narasimhan, Leah J. Novinger, Austin S. Keith, Teresa A. Zimmers, Monte S. Willis, Andrea Bonetto
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2020)
Article
Biochemistry & Molecular Biology
Joshua R. Huot, Fabrizio Pin, Alyson L. Essex, Andrea Bonetto
Summary: Colorectal cancer (CRC) is a leading cause of cancer-related death, and a new study established a metastatic CRC cachexia model, confirming the concept that liver metastases (LM) exacerbate cachexia.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Riccardo Ballaro, Patrizia Lopalco, Valentina Audrito, Marc Beltra, Fabrizio Pin, Roberto Angelini, Paola Costelli, Angela Corcelli, Andrea Bonetto, Hazel H. Szeto, Thomas M. O'Connell, Fabio Penna
Summary: Cancer cachexia is a debilitating syndrome caused by tumor growth and chemotherapy, affecting skeletal muscle metabolism and function. The study focused on using the mitochondria-targeted compound SS-31 to counteract cachexia by improving metabolic function, showing effectiveness in early disease stages but limited effects in late refractory cachexia. Targeting mitochondrial function may be important in preventing cancer cachexia, with potential for multi-modal therapies including SS-31.
Review
Cell Biology
Juha J. Hulmi, Tuuli A. Nissinen, Fabio Penna, Andrea Bonetto
Summary: Muscle wasting, known as cachexia, is common in cancer patients and is associated with poor prognosis. Anticancer treatments may exacerbate cachexia. Preclinical studies have shown that blocking ACVR2 signaling can preserve muscle mass and improve survival, but further research is needed to determine if improved survival directly results from muscle preservation.
Review
Medicine, Research & Experimental
Fabrizio Pin, Lynda F. Bonewald, Andrea Bonetto
Summary: Cancer-induced muscle wasting, or cachexia, is a common and debilitating feature in cancer patients, leading to musculoskeletal alterations. Communication between muscle and bone through cell factors is important in this process, with myokines and osteokines playing key roles in cancer-induced cachexia.
EXPERIMENTAL BIOLOGY AND MEDICINE
(2021)
Article
Immunology
Joseph E. Rupert, Ashok Narasimhan, Daenique H. A. Jengelley, Yanlin Jiang, Jianguo Liu, Ernie Au, Libbie M. Silverman, George Sandusky, Andrea Bonetto, Sha Cao, Xiaoyu Lu, Thomas M. O'Connell, Yunlong Liu, Leonidas G. Koniaris, Teresa A. Zimmers
Summary: The study revealed that most patients with pancreatic adenocarcinoma suffer from cachexia, which is mainly due to tissue crosstalk mediated via IL-6 signaling affecting muscle and adipocytes, providing targetable mechanisms for cachexia treatment.
JOURNAL OF EXPERIMENTAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Fabrizio Pin, Alexander J. Jones, Joshua R. Huot, Ashok Narasimhan, Teresa A. Zimmers, Lynda F. Bonewald, Andrea Bonetto
Summary: This study demonstrates that patients with ovarian cancer exhibit evidence of cachexia and increased bone turnover, with high levels of RANKL potentially causing skeletal muscle atrophy and bone resorption. Treatment with antiresorptive and anti-RANKL therapies benefits muscle mass and function in cancer cachexia.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Endocrinology & Metabolism
Fabrizio Pin, Matt Prideaux, Lynda F. Bonewald, Andrea Bonetto
Summary: This review explores the interaction between osteocytes and cancer, focusing on their involvement in osteosarcoma and multiple myeloma, as well as the mechanisms of cancer dissemination to bone. It discusses the dual role of osteocytes in both promoting cancer cell proliferation and providing protective effects against bone colonization, highlighting the complexity of their role in cancer progression and dissemination. Additionally, it presents findings suggesting that the bone microenvironment, particularly osteocytes, can respond dramatically to non-metastatic tumors, prompting further studies on the potential combination of osteocyte-preserving treatments with traditional anticancer therapies.
CURRENT OSTEOPOROSIS REPORTS
(2021)
Article
Endocrinology & Metabolism
Alyson L. Essex, Joshua R. Huot, Padmini Deosthale, Alison Wagner, Jorge Figueras, Azaria Davis, John Damrath, Fabrizio Pin, Joseph Wallace, Andrea Bonetto, Lilian Plotkin
Summary: This study reveals that the Trem2 variant associated with Alzheimer's disease risk may independently affect bone and skeletal muscle loss, regardless of central nervous system defects. These findings suggest a potential link between Trem2 signaling alterations and skeletal health.
JOURNAL OF BONE AND MINERAL RESEARCH
(2022)
Review
Endocrinology & Metabolism
Chandler S. Callaway, Lila M. Mouchantat, Benjamin G. Bitler, Andrea Bonetto
Summary: Cancer-associated cachexia is a common occurrence in cancer patients, including those with ovarian cancer. Reduced skeletal muscle mass in ovarian cancer patients is associated with worse outcomes. Mouse models show characteristics of cachexia in ovarian cancer, but there is limited research on ovarian cancer-associated cachexia compared to other cancer types. Certain soluble factors may serve as therapeutic targets for mitigating cachexia in ovarian cancer. However, more research is needed to determine the translational relevance of these findings due to the relatively low number of studies.
Article
Otorhinolaryngology
Alexander Joseph Jones, Vincent J. Campiti, Mohamedkazim Alwani, Leah J. Novinger, Brady Jay Tucker, Andrea Bonetto, Jessica A. Yesensky, Michael W. Sim, Michael G. Moore, Avinash V. Mantravadi
Summary: The study aimed to determine if sarcopenia is a predictor of blood transfusion requirements in head and neck cancer free flap reconstruction. Results showed that sarcopenia, comorbidity severity, preoperative hemoglobin level, operative time, and estimated blood loss were independent predictors of intraoperative transfusion requirements. Postoperative transfusions were mainly associated with major complications.
LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY
(2021)